Method of treating neonates with igf-1 complex
AssigneeOak Hill Bio Limited
InventorsGalen John CAREY, Norman Walter BARTON, David Charles Reginald LEY, Claes Per EKSTRÖM, Magnus Göran GRAM, Niklas Emanuel ORTENLÖF
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and/or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500 μg/Kg/day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and/or protection from circulatory collapse.
Claims15
-17. (canceled)
A method of treatment for prevention of intraventricular haemorrhage (IVH) and prevention/reduction of mortality for all causes in a preterm infant at a gestational age of 23 to 26 weeks comprising administering a complex of IGF-1 and IGFBP-3 via continuous infusion at a dose of 350-500 μg/Kg/day, for a period of at least 7 days,
- such that plasma levels of IGF-1 are maintained within the therapeutic range 28 μg/L to 109 μg/L during the treatment period,
- wherein after exclusion of baseline assessment timepoint more than 60% of those infants receiving treatment are IVH free, and
- pathological fluctuations in blood osmolarity are stabilised.
A method of preventing IVH and prevention/reduction of mortality for all causes in a preterm infant at a gestational age of 23 to 26 weeks by administering via continuous infusion a composition comprising a complex of IGF-1 and IGFBP-3, at a dose of 350-500 μg/Kg/day, for a period of at least 7 days,
- such that plasma levels of IGF-1 are maintained within the therapeutic range 28 μg/L to 109 μg/L during the treatment period,
- wherein after exclusion of baseline assessment timepoint more than 60% of those infants receiving treatment are IVH free.
Dependencies are inferred from the claim text.